Radiosensitization of esophageal carcinoma cells by knockdown of HMGB1 expression

Zhang,Xueyuan; Yang,Xingxiao; Zhu,Shuchai; Li,Qiaofang; Zou,Naiyi

doi:10.3892/or.2018.6923

Radiosensitization of esophageal carcinoma cells by knockdown of HMGB1 expression

Authors:
- Xueyuan Zhang
- Xingxiao Yang
- Shuchai Zhu
- Qiaofang Li
- Naiyi Zou
View Affiliations

Affiliations: Department of Radiation Oncology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei 050011, P.R. China, Department of Infection Management, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei 050011, P.R. China
Published online on: December 10, 2018 https://doi.org/10.3892/or.2018.6923
Pages: 1960-1970

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Radiotherapy (RT) is a traditional and important treatment for carcinoma of the esophagus along with surgery and chemotherapy. High mobility group box 1 (HMGB1) plays a crucial part in inhibiting the apoptosis of cancer cells after irradiation treatment. The present study, was designed to analyze the function of HMGB1 in esophageal cancer progression and elucidate the effects of HMGB1 on the radiosensitivity of human esophageal cancer cell lines. In the present study, an immunohistochemical evaluation of HMGB1 was performed on 77 biopsies, and the results revealed that HMGB1 overexpression was positively correlated with gross tumor volume (GTV), tumor‑node‑metastasis (TNM) stage, T classification, distant metastasis, and relapse and negatively correlated with patient survival rates, suggesting that HMGB1 acts as a key factor in the development of esophageal cancer. An shRNA targeting HMGB1 was designed for the knockdown of HMGB1 in ECA109 and TE13 cells, and the transfection efficiency of the shRNA was assessed using quantitative real‑time reverse transcription polymerase chain reaction and western blot analysis. CCK‑8 and clonogenic assays were used to analyze the effect of HMGB1 on the proliferation and radiosensitivity, respectively, of esophageal cancer cells in vitro. The influence of HMGB1 on radiation‑induced changes in the migration, invasion, and cell cycle as well as apoptosis of tumor cells was examined by wound‑healing and Transwell assays and flow cytometry, respectively. In addition, xenograft tumor models were constructed to observe the effect of HMGB1 on tumor growth in vivo. The results of the study in vitro revealed that the proliferation of the HMGB1‑shRNA group decreased after irradiation, and the radiation treatment reduced the tumor volume of the xenograft model which was more marked in HMGB1‑shRNA group. Moreover, HMGB1 was involved in the phosphorylation of H2AX after irradiation, and HMGB1 knockdown blocked the cell cycle in the G0/G1 phase and increased apoptosis. HMGB1 deficiency was also correlated with the upregulation of p16, Bax and caspase‑9 and the downregulation of MMP‑2, MMP‑9, cyclin D1, CDK4, γH2AX and Bcl‑2. These data indicated that the overexpression of HMGB1 prior to treatment was correlated with poor clinical outcome in esophageal carcinoma and that knockdown HMGB1 expression in human esophageal cancer cell lines increased their radiosensitivity by allowing the induction of apoptosis and G0/G1 arrest after exposure to radiation.

View Figures

View References

1	Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
2	Pennathur A, Gibson MK, Jobe BA and Luketich JD: Oesophageal carcinoma. Lancet. 381:400–412. 2013. View Article : Google Scholar : PubMed/NCBI
3	Ishihara R, Yamamoto S, Iishi H, Takeuchi Y, Sugimoto N, Higashino K, Uedo N, Tatsuta M, Yano M, Imai A, et al: Factors predictive of tumor recurrence and survival after initial complete response of esophageal squamous cell carcinoma to definitive chemoradiotherapy. Int J Radiat Oncol Biol Phys. 76:123–129. 2010. View Article : Google Scholar : PubMed/NCBI
4	Tang D, Kang R, Zeh HJ III and Lotze MT: High-mobility group box 1 and cancer. Biochim Biophys Acta 1799. 131–140. 2010.
5	Kang R, Zhang Q, Zeh HJ III, Lotze MT and Tang D: HMGB1 in cancer: Good, bad, or both? Clin Cancer Res. 19:4046–4057. 2013. View Article : Google Scholar : PubMed/NCBI
6	Yuan F, Gu L, Guo S, Wang C and Li GM: Evidence for involvement of HMGB1 protein in human DNA mismatch repair. J Biol Chem. 279:20935–20940. 2004. View Article : Google Scholar : PubMed/NCBI
7	Lange SS, Mitchell DL and Vasquez KM: High mobility group protein B1 enhances DNA repair and chromatin modification after DNA damage. Proc Natl Acad Sci USA. 105:10320–10325. 2008. View Article : Google Scholar : PubMed/NCBI
8	Shrivastava S, Mansure JJ, Almajed W, Cury F, Ferbeyre G, Popovic M, Seuntjens J and Kassouf W: The role of HMGB1 in radioresistance of bladder cancer. Mol Cancer Ther. 15:471–479. 2016. View Article : Google Scholar : PubMed/NCBI
9	Lin HJ, Liu HH, Lin CD, Kao MC, Chen YA, Chiang-Ni C, Jiang ZP, Huang MZ, Lin CJ, Lo UG, et al: Cytolethal distending toxin enhances radiosensitivity in prostate cancer cells by regulating autophagy. Front Cell Infect Microbiol. 7:2232017. View Article : Google Scholar : PubMed/NCBI
10	Ke S, Zhou F, Yang H, Wei Y, Gong J, Mei Z, Wu L, Yu H and Zhou Y: Downregulation of high mobility group box 1 modulates telomere homeostasis and increases the radiosensitivity of human breast cancer cells. Int J Oncol. 46:1051–1058. 2015. View Article : Google Scholar : PubMed/NCBI
11	Hongo K, Kazama S, Tsuno NH, Ishihara S, Sunami E, Kitayama J and Watanabe T: Immunohistochemical detection of high-mobility group box 1 correlates with resistance of preoperative chemoradiotherapy for lower rectal cancer: A retrospective study. World J Surg Oncol. 13:72015. View Article : Google Scholar : PubMed/NCBI
12	Soumaoro LT, Uetake H, Higuchi T, Takagi Y, Enomoto M and Sugihara K: Cyclooxygenase-2 expression: A significant prognostic indicator for patients with colorectal cancer. Clin Cancer Res. 10:8465–8471. 2004. View Article : Google Scholar : PubMed/NCBI
13	Wu D, Ding Y, Wang S, Zhang Q and Liu L: Increased expression of high mobility group box 1 (HMGB1) is associated with progression and poor prognosis in human nasopharyngeal carcinoma. J Pathol. 216:167–175. 2008. View Article : Google Scholar : PubMed/NCBI
14	Boonstra JJ, van der Velden AW, Beerens EC, van Marion R, Morita-Fujimura Y, Matsui Y, Nishihira T, Tselepis C, Hainaut P, Lowe AW, et al: Mistaken identity of widely used esophageal adenocarcinoma cell line TE-7. Cancer Res. 67:7996–8001. 2007. View Article : Google Scholar : PubMed/NCBI
15	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2^ΔΔCT method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
16	Yang XX, Ma M, Sang MX, Wang XX, Song H, Liu ZK and Zhu SC: Radiosensitization of esophageal carcinoma cells by knockdown of RNF2 expression. Int J Oncol. 48:1985–1996. 2016. View Article : Google Scholar : PubMed/NCBI
17	Zhang Y: Epidemiology of esophageal cancer. World J Gastroenterol. 19:5598–5606. 2013. View Article : Google Scholar : PubMed/NCBI
18	Sohun M and Shen H: The implication and potential applications of high-mobility group box 1 protein in breast cancer. Ann Transl Med. 4:2172016. View Article : Google Scholar : PubMed/NCBI
19	Jiang H, Hu X, Zhang H and Li W: Down-regulation of LncRNA TUG1 enhances radiosensitivity in bladder cancer via suppressing HMGB1 expression. Radiat Oncol. 12:652017. View Article : Google Scholar : PubMed/NCBI
20	Shi Z, Huang Q, Chen J, Yu P, Wang X, Qiu H, Chen Y and Dong Y: Correlation of HMGB1 expression to progression and poor prognosis of adenocarcinoma and squamous cell/adenosquamous carcinoma of gallbladder. Am J Transl Res. 7:2015–2025. 2015.PubMed/NCBI
21	Tabata C, Shibata E, Tabata R, Kanemura S, Mikami K, Nogi Y, Masachika E, Nishizaki T and Nakano T: Serum HMGB1 as a prognostic marker for malignant pleural mesothelioma. BMC Cancer. 13:2052013. View Article : Google Scholar : PubMed/NCBI
22	Peng T, Hu M, Wu T, Chen Z, Zhang C, Huang S and Zhou X: Effects of high-mobility group box 1 knockdown on proliferation, migration and invasion of the HONE-1 human nasopharyngeal carcinoma cell line. Mol Med Rep. 12:7531–7537. 2015. View Article : Google Scholar : PubMed/NCBI
23	Suzuki Y, Mimura K, Yoshimoto Y, Watanabe M, Ohkubo Y, Izawa S, Murata K, Fujii H, Nakano T and Kono K: Immunogenic tumor cell death induced by chemoradiotherapy in patients with esophageal squamous cell carcinoma. Cancer Res. 72:3967–3976. 2012. View Article : Google Scholar : PubMed/NCBI
24	Gebhardt C, Riehl A, Durchdewald M, Németh J, Fürstenberger G, Müller-Decker K, Enk A, Arnold B, Bierhaus A, Nawroth PP, et al: RAGE signaling sustains inflammation and promotes tumor development. J Exp Med. 205:275–285. 2008. View Article : Google Scholar : PubMed/NCBI
25	Liu Z, Falo LD Jr and You Z: Knockdown of HMGB1 in tumor cells attenuates their ability to induce regulatory T cells and uncovers naturally acquired CD8 T cell-dependent antitumor immunity. J Immunol. 187:118–125. 2011. View Article : Google Scholar : PubMed/NCBI
26	van Beijnum JR, Nowak-Sliwinska P, van den Boezem E, Hautvast P, Buurman WA and Griffioen AW: Tumor angiogenesis is enforced by autocrine regulation of high-mobility group box 1. Oncogene. 32:363–374. 2013. View Article : Google Scholar : PubMed/NCBI
27	Giavara S, Kosmidou E, Hande MP, Bianchi ME, Morgan A, d'Adda di Fagagna F and Jackson SP: Yeast Nhp6A/B and mammalian Hmgb1 facilitate the maintenance of genome stability. Curr Biol. 15:68–72. 2005. View Article : Google Scholar : PubMed/NCBI
28	Tang D, Kang R, Livesey KM, Kroemer G, Billiar TR, Van Houten B, Zeh HJ III and Lotze MT: High-mobility group box 1 is essential for mitochondrial quality control. Cell Metab. 13:701–711. 2011. View Article : Google Scholar : PubMed/NCBI
29	Taguchi A, Blood DC, del Toro G, Canet A, Lee DC, Qu W, Tanji N, Lu Y, Lalla E, Fu C, et al: Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases. Nature. 405:354–360. 2000. View Article : Google Scholar : PubMed/NCBI
30	Livesey KM, Kang R, Vernon P, Buchser W, Loughran P, Watkins SC, Zhang L, Manfredi JJ, Zeh HJ III, Li L, et al: p53/HMGB1 complexes regulate autophagy and apoptosis. Cancer Res. 72:1996–2005. 2012. View Article : Google Scholar : PubMed/NCBI
31	Krynetskaia NF, Phadke MS, Jadhav SH and Krynetskiy EY: Chromatin-associated proteins HMGB1/2 and PDIA3 trigger cellular response to chemotherapy-induced DNA damage. Mol Cancer Ther. 8:864–872. 2009. View Article : Google Scholar : PubMed/NCBI
32	Soutoglou E and Misteli T: Activation of the cellular DNA damage response in the absence of DNA lesions. Science. 320:1507–1510. 2008. View Article : Google Scholar : PubMed/NCBI
33	Krynetskaia N, Xie H, Vucetic S, Obradovic Z and Krynetskiy E: High mobility group protein B1 is an activator of apoptotic response to antimetabolite drugs. Mol Pharmacol. 73:260–269. 2008. View Article : Google Scholar : PubMed/NCBI
34	Kessenbrock K, Wang CY and Werb Z: Matrix metalloproteinases in stem cell regulation and cancer. Matrix Biol. 44-46:184–190. 2015. View Article : Google Scholar : PubMed/NCBI
35	Lee CC, Wang CN, Lee YL, Tsai YR and Liu JJ: High mobility group box 1 induced human lung myofibroblasts differentiation and enhanced migration by activation of MMP-9. PLoS One. 10:e01163932015. View Article : Google Scholar : PubMed/NCBI
36	Agami R and Bernards R: Distinct initiation and maintenance mechanisms cooperate to induce G1 cell cycle arrest in response to DNA damage. Cell. 102:55–66. 2000. View Article : Google Scholar : PubMed/NCBI
37	Cheng P, Dai W, Wang F, Lu J, Shen M, Chen K, Li J, Zhang Y, Wang C, Yang J, et al: Ethyl pyruvate inhibits proliferation and induces apoptosis of hepatocellular carcinoma via regulation of the HMGB1-RAGE and AKT pathways. Biochem Biophys Res Commun. 443:1162–1168. 2014. View Article : Google Scholar : PubMed/NCBI
38	Allan LA and Clarke PR: Apoptosis and autophagy: Regulation of caspase-9 by phosphorylation. FEBS J. 276:6063–6073. 2009. View Article : Google Scholar : PubMed/NCBI